by Sean Hughes | Oct 1, 2019 | Briefings, US & International
Background US patents have a term of 20 years from the filing date of the patent application. A long period of prosecution, however, can effectively diminish the patent term, since a patent is only enforceable after grant. In an effort to make things fairer, the USPTO...
by | Oct 1, 2019 | Briefings, EPO
Division was held to be enough for remittal to be ordered. T 688/16 T 688/16 relates to an appeal of the Decision of an Opposition Division to revoke EP2053959, a patent related to a method for assessing and guaranteeing the thermal hygiene efficiency in a multi-tank...
by David Eyre | Sep 1, 2019 | Briefings, US & International
Eli Lilly is the patent holder of a drug called pemetrexed (Lilly brand “Alimta”) that has been the subject of court proceedings in the UK, which we have reported previously. This case concerns a related issue during US proceedings in which the US Federal...
by Carolyn Haywood | Sep 1, 2019 | Briefings, EPO
J 0015/18 is a case concerning an appeal against the decision of the Receiving Section issued on European patent application no. 11827111.3 (originating from International patent application no. PCT/US2011/037235 ) to refuse a request filed under Rule 139 EPC to...
by Sean Hughes | Aug 1, 2019 | UK
Background In Illumina v TDL & Ariosa [2019] EWHC 1159, an interesting question at hand was whether Illumina had to get the Court’s permission to rely on expert evidence which was used in a different case and then served under a hearsay notice in the present...
Recent Comments